[68Ga]Ga-RAYZ-8009:靶向磷脂酰肌醇蛋白聚糖-3的肝细胞癌分子影像诊断放射性药物——首次人体病例系列
本研究首次在已知或疑似肝细胞癌患者中评估[68Ga]Ga-RAYZ-8009(一种靶向GPC3的肽类配体)PET/CT显像的安全性与成像效果,共扫描24例患者、分析50个病灶,未见不良事件,病灶平均SUVmax为19.6,非肿瘤肝与本底快速清除,作者认为其安全且可实现高对比度成像,值得进一步研究。
要点
- 24例患者扫描未见不良事件,2例随访无病灶且非肝细胞癌。
- 50个病灶约60分钟时平均SUVmax 19.6、平均SUVmean 10.1。
- 非肿瘤肝与本底45分钟后平均SUVmean<1.6,4小时降至1.0。
核心结论
- [68Ga]Ga-RAYZ-8009安全,可实现GPC3阳性肝细胞癌的高对比度成像,大多数正常器官清除快。
- 作者认为[68Ga]Ga-RAYZ-8009有望用于肝细胞癌诊断与分期,并指出需进一步研究。
研究设计与样本
- 首次人体病例系列,纳入已知或疑似肝细胞癌患者,其中动态协议5例、静态协议19例,共24例接受[68Ga]Ga-RAYZ-8009 PET/CT扫描。
- 示踪剂由68Ge/68Ga发生器获得68Ga标记肽前体,90°C加热10分钟后无菌过滤制得,给药后45分钟至4小时采集动态或静态PET/CT。
主要发现
- 24例患者扫描未见不良事件;2例未检出病灶且随访期间无肝细胞癌。
- 共检出并分析50个病灶,给药约60分钟时病灶平均SUVmax为19.6(范围2.7-95.3),平均SUVmean为10.1(范围1.0-49.2)。
- 非肿瘤肝与本底摄取随时间快速下降,给药45分钟后平均SUVmean<1.6,至4小时持续降至平均SUVmean 1.0。
- 肝细胞癌病灶的SUV与肿瘤-健康肝比值(TLR)在给药后持续升高至4小时,单个病灶分析中TLR在给药后60至120分钟最高。
- 胃底摄取在给药后逐渐升高至45分钟(SUVmax 31.3),此后逐渐下降。
局限性
- 作者指出需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date, the imaging and diagnosis of hepatocellular carcinoma (HCC) rely on CT/MRI, which have well-known limitations. Glypican-3 (GPC3) is a cell surface receptor highly expressed by HCC but not by normal or cirrhotic liver tissue. Here we report initial clinical results of GPC3-targeted PET imaging with [68Ga]Ga-DOTA-RYZ-GPC3 (RAYZ-8009), a peptide-based GPC3 ligand in patients with known or suspected HCC. Methods: [68Ga]Ga-RAYZ-8009 was obtained after labeling the peptide precursor with 68Ga from a 68Ge/68Ga generator and heating at 90°C for 10 min followed by sterile filtration. After administration of [68Ga]Ga-RAYZ-8009, a dynamic or static PET/CT scan was acquired between 45 min and 4 h after administration. Radiotracer uptake was measured by SUVs for the following tissues: suspected or actual HCC or hepatoblastoma lesions, non-tumor-bearing liver, renal cortex, blood pool in the left ventricle, and gastric fundus. Additionally, tumor-to-healthy-liver ratios (TLRs) were calculated. Results: Twenty-four patients (5 patients in the dynamic protocol; 19 patients in the static protocol) were scanned. No adverse events occurred. Two patients had no lesion detected and did not have HCC during follow-up. In total, 50 lesions were detected and analyzed. The mean SUVmax of these lesions was 19.6 (range, 2.7-95.3), and the mean SUVmean was 10.1 (range, 1.0-49.2) at approximately 60 min after administration. Uptake in non-tumor-bearing liver and blood pool rapidly decreased over time and became negligible 45 min after administration (mean SUVmean, <1.6), with a continuous decline to 4 h after administration (mean SUVmean, 1.0). The opposite was observed for HCC lesions, for which SUVs and TLRs continuously increased for up to 4 h after administration. In individual lesion analysis, TLR was the highest between 60 and 120 min after administration. Uptake in the gastric fundus gradually increased for up to 45 min (to an SUVmax of 31.3) and decreased gradually afterward. Conclusion: [68Ga]Ga-RAYZ-8009 is safe and allows for high-contrast imaging of GPC3-positive HCC, with rapid clearance from most normal organs. Thereby, [68Ga]Ga-RAYZ-8009 is promising for HCC diagnosis and staging. Further research is warranted.
引用
- Poot AJ, Lapa C, Weber WA, et al. [68Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series. J Nucl Med. 2024. PMID: 39266293. doi:10.2967/jnumed.124.268147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。